SLC5A2 and type 2 diabetes mellitus: The keywords used for the literature search were related to SGLT2 inhibitors (“dapagliflozin,” “empagliflozin,” “canagliflozin,” “ertugliflozin,” and “sotagliflozin”), “heart failure” (“HFrEF” and “HFpEF), “type 2 diabetes,” and “cardiovascular and renal outcome with SGLT2 inhibitors.” The inclusion criteria for this review were limited to randomized control trials (RCTs) published between 2012 and 2022 and in the English language.